<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the effect of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> compared to <z:chebi fb="0" ids="2668">amlodipine</z:chebi> on QT duration and dispersion in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A total of 170 outpatients aged 50-75 years with mild to moderate <z:hpo ids='HP_0000822'>hypertension</z:hpo> (SBP &gt;130 and &lt;180 mmHg and <z:chebi fb="4" ids="35861">DBP</z:chebi> &gt;80 and &lt;100 mmHg) and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomly treated with <z:chebi fb="0" ids="601027">aliskiren</z:chebi> 300 mg or <z:chebi fb="0" ids="2668">amlodipine</z:chebi> 10 mg, both given once daily for 24 weeks, according to a prospective, open label, blinded-end point, parallel group design </plain></SENT>
<SENT sid="2" pm="."><plain>At the end of the placebo run-in, and after 12, and 24 weeks of treatment blood pressure (BP) measurements (by mercury sphygmomanometer, Korotkoff I and V), plasma biochemistry and a standard 12-lead surface ECG were evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Both <z:chebi fb="0" ids="601027">aliskiren</z:chebi> and <z:chebi fb="0" ids="2668">amlodipine</z:chebi> significantly <z:mp ids='MP_0006264'>reduced systolic blood pressure</z:mp> (SBP)/diastolic blood pressure (<z:chebi fb="4" ids="35861">DBP</z:chebi>) values (-27.2/-14.3 mmHg, p &lt; 0.001 vs. placebo and -27.8/-14.2 mmHg, p &lt; 0.001 vs. placebo, respectively), with no statistical difference between the two drugs </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="601027">Aliskiren</z:chebi>, but not <z:chebi fb="0" ids="2668">amlodipine</z:chebi>, significantly reduced maximum QT interval (QTmax) (-14 ms at 12 weeks and -17 ms at 24 weeks, both p &lt; 0.05 vs. placebo) and corrected QT max (QTc max) (-26 ms and -31 ms, p &lt; 0.01) as well as the dispersion of both QT (-11 ms and -13 ms, p &lt; 0.01) and QTc (-18 ms and -19 ms, p &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Despite similar BP lowering effect, <z:chebi fb="0" ids="601027">aliskiren</z:chebi>, but not <z:chebi fb="0" ids="2668">amlodipine</z:chebi>, reduced QT duration and dispersion, which might be related to the ability of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> to interfere with mechanisms underlying myocardial electrical instability in the heart of diabetic hypertensive patients </plain></SENT>
</text></document>